Knight Therapeutics Doubles Down on Earnings Momentum

Knight Therapeutics ((TSE:GUD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Knight Therapeutics’ latest earnings call struck an upbeat tone, underscoring strong momentum in both operations and finances. Management highlighted record quarterly revenue and adjusted EBITDA, a firmer balance sheet, and a busy launch and business development pipeline, while acknowledging rising costs, regulatory delays and macro risks that could temper performance in specific markets.

Record Revenue Growth Fuels Top-Line Momentum

Knight reported record first-quarter 2026 revenue of $148 million, expanding roughly 68–69% from the prior year as acquisitions and promoted brands kicked in. Management pointed to incremental contributions from the Sumitomo and Paladin portfolios, stronger promoted products and favorable customer purchasing patterns as key growth drivers.

Profitability Surges With Record Adjusted EBITDA

Adjusted EBITDA climbed to a record $28 million, more than doubling year-over-year with growth of about 130%. On a per-share basis, adjusted EBITDA reached $0.28, up roughly 133%, signaling that earnings power is scaling faster than the share base and bolstering the investment case.

Gross Margin Strength Underpins Earnings Quality

Adjusted gross margin rose to $70.6 million, representing 48% of revenue versus 47% in the prior-year quarter, driven largely by higher sales. The modest but meaningful margin expansion suggests Knight is converting incremental revenue into profit efficiently, even as it absorbs integration and launch costs across its growing portfolio.

Balance Sheet and Liquidity Position Strengthen

Operating cash flow reached $41 million in the quarter, allowing Knight to end Q1 with $127 million in cash and marketable securities and net cash of about $69 million. Debt stood near $58 million and leverage fell below 0.7 times adjusted EBITDA, aided by repayment of most of a previously drawn revolving facility, giving the company financial flexibility.

Regulatory Wins and New Launches Broaden Footprint

Knight reported notable regulatory progress, including filings for Niktimvo in Brazil and Minjuvi for follicular lymphoma in Argentina and Mexico, plus Brazilian approval of Minjuvi’s second indication. The company has already executed four launches in 2026, rolling out Minjuvi FL in Brazil, Pemazyre in Argentina, Akynzeo in Paraguay and Bapocil in Colombia, deepening its presence across Latin America.

Robust Launch Pipeline Offers Medium-Term Upside

Over the past two years Knight has completed around 15 launches and expects about 10 more in 2026, underlining a steady flow of new products. Management estimates the pipeline could generate roughly $200 million in peak revenue, with about $40 million already materializing on a trailing 12-month basis, indicating meaningful embedded growth.

Promoted and Strategic Products Drive Revenue Mix

Incremental first-quarter revenue was well diversified: mature Paladin and Sumitomo products added about $17 million, launch-pipeline items contributed around $13 million and strategic products accounted for roughly $28 million. Ambisome alone delivered an incremental $14 million, underscoring its importance as a flagship therapy within Knight’s broader portfolio.

Share Buybacks Signal Confidence in Valuation

Knight repurchased 1.3 million shares in the quarter at an average price of $6.22, deploying $8.2 million of cash toward its normal course issuer bid. To date the company has bought back 2 million shares and retains capacity for an additional 4.2 million through August 2026, suggesting management views the stock as undervalued and prioritizes shareholder returns.

Raised 2026 Outlook Reflects Stronger Momentum

The company lifted its fiscal 2026 guidance, now targeting revenue between $510 million and $525 million and adjusted EBITDA near 15% of sales. Management attributed the upgrade to better-than-expected performance of promoted products in Canada, Mexico and Colombia, along with an estimated $5–$10 million foreign-exchange tailwind, indicating improved visibility on growth.

Business Development Pipeline Remains Active

Beyond its recent large portfolio deals, Knight highlighted a steady stream of in-licensing and acquisition opportunities in its core markets. Historically the company has added about three products per year, and management sees continued healthy deal flow, supporting its strategy of building a diversified specialty pharma platform across Canada and Latin America.

Qelbree Filing Withdrawal Delays Canadian Launch

Knight withdrew its new drug submission for Qelbree in Canada after manufacturing changes by its partner required updated data for regulators. Management expects to refile once the necessary manufacturing and technical information is assembled, but now anticipates a launch delay of roughly one to two years, pushing out expected revenue from the asset.

Operating Expenses Climb With Portfolio Expansion

Operating expenses excluding amortization rose to $43 million, a 44% year-over-year increase as Knight invested in infrastructure and commercial capabilities. Management emphasized that the higher cost base reflects support for a larger product portfolio and multiple simultaneous launches, which they believe will pay off through future revenue and earnings growth.

Net Loss Tied to Investment Revaluations

Despite strong operating performance, Knight reported a net loss of $2.8 million in the quarter due to mark-to-market adjustments on strategic fund and equity holdings valued around $95 million. These non-cash revaluations highlight some earnings volatility tied to financial investments, though they do not alter the company’s underlying cash generation.

Generic Threats Cast Shadow on Ambisome and Others

Management flagged potential medium-term risks from generic competition, particularly for Ambisome, even as it currently benefits from a ministry of health contract and limited generic supply. Generic versions are under review in Brazil and already exist in the U.S., and while branded generics in Latin America typically erode sales gradually over three to five years, the company acknowledges a material risk to long-term revenue.

Mature Product Headwinds and Portfolio Pruning

Some of Knight’s mature brands are expected to be flat to slightly declining, in line with their lifecycle stage. In addition, a few older products previously acquired will be returned, which management estimates will trim about $7 million annually from revenue, reflecting a deliberate decision to focus on more strategic, higher-growth assets.

Argentina Hyperinflation and FX Sensitivity

Knight’s upgraded guidance assumes no significant impact from hyperinflation accounting in Argentina, a market that remains volatile. Management noted that recent currency movements contributed roughly $5–$10 million to the outlook, highlighting that foreign-exchange swings could still meaningfully influence reported results and investor expectations.

Guidance Signals Confidence but Flags Macro Risks

Overall guidance calls for 2026 revenue of $510–$525 million and adjusted EBITDA of roughly $76.5–$78.8 million, implying healthy growth from Q1’s record baseline. The outlook embeds about 10 planned launches this year, higher promoted-product performance and FX benefits, but also rests on stable conditions in markets like Argentina, leaving some macro risk on the horizon.

Knight Therapeutics’ earnings call painted a picture of a company hitting its stride, combining record revenue and profitability with a strengthened balance sheet and a sizable launch pipeline. While rising costs, regulatory delays and exposure to generics and hyperinflation pose challenges, management’s upgraded guidance and continued investment signal confidence that growth will outweigh these risks for shareholders.